Kiora Pharmaceuticals (NASDAQ:KPRX) Trading 0.6% Higher – Should You Buy?

Shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) were up 0.6% during trading on Monday . The stock traded as high as $3.36 and last traded at $3.29. Approximately 33,873 shares changed hands during trading, a decline of 52% from the average daily volume of 70,291 shares. The stock had previously closed at $3.27.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Kiora Pharmaceuticals in a report on Tuesday, November 12th.

Kiora Pharmaceuticals Price Performance

The stock has a 50-day moving average price of $3.48 and a two-hundred day moving average price of $4.04.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.09. On average, equities research analysts anticipate that Kiora Pharmaceuticals, Inc. will post 0.89 earnings per share for the current year.

Institutional Investors Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC bought a new position in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals makes up approximately 0.8% of Stonepine Capital Management LLC’s portfolio, making the stock its 16th biggest holding. Stonepine Capital Management LLC owned 6.86% of Kiora Pharmaceuticals at the end of the most recent quarter. Institutional investors own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.